Estrella Immunopharma, Inc.
ESLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,153 | $4,660 | $1,410 | $33 |
| G&A Expenses | $649 | $884 | $694 | $0 |
| SG&A Expenses | $649 | $884 | $694 | $1,018 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,801 | $5,544 | $2,104 | $1,050 |
| Operating Income | -$4,801 | -$5,544 | -$2,104 | -$1,050 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4,801 | -$5,544 | -$2,104 | -$1,050 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$4,801 | -$5,545 | -$2,104 | -$1,050 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.15 | -0.058 | -0.029 |
| % Growth | 13.3% | -157.7% | -103.5% | – |
| EPS Diluted | -0.13 | -0.15 | -0.058 | -0.029 |
| Weighted Avg Shares Out | 37,096 | 36,166 | 36,188 | 36,681 |
| Weighted Avg Shares Out Dil | 37,096 | 36,166 | 36,188 | 36,681 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4,801 | -$5,544 | -$2,104 | -$1,050 |
| % Margin | – | – | – | – |